Legend Biotech reports Q3 2026 results, CARVYKTI sales up 36%, names new CEO

Legend Biotech Corporation reported third quarter 2026 results on November 10, 2026, disclosing that compared to the third quarter of 2025, CARVYKTI net trade sales increased 36% in the third quarter of 2026 to approximately $710 million, with U.S. net trade sales growth of 19% and ex-U.S. net trade sales growth of 86%.¹ The therapy is now available across 373 treatment sites in 20 global markets.¹

On the clinical side, the company presented five-year data from CARTITUDE-2 (NCT04133636) Cohort A, which evaluated patients with relapsed or refractory multiple myeloma after one to three prior lines of therapy (n=20; median follow-up, 60.7 months), at the 23rd International Myeloma Society Annual Meeting in September.¹ The company said with a median follow-up of 60.7 months, 10 of 20 patients (50%) remained alive and progression-free without further anti-myeloma treatment five years or more after a single CARVYKTI infusion.¹ Median overall survival was not reached at the time of analysis, and 69.2% of patients were alive at five years.¹ The safety profile with longer follow-up was consistent with prior observations, with no new CAR-T-cell-related neurotoxicity reported, though since the prior analysis at roughly 30 months one patient developed acute myeloid leukemia and two deaths occurred from progressive disease and a new cancer.¹

Separately, Legend said it received FDA clearance of the investigational new drug application for LB2501, described as a CD19/CD20 dual-targeting therapy delivered inside the body to generate CAR-T cells, intended for relapsed or refractory B-cell cancers such as B-cell non-Hodgkin lymphoma.¹ The company noted this candidate is designed to work by generating CAR-T cells directly within the patient after a single intravenous infusion, which the company said makes it the first dual-targeting in vivo CAR-T therapy of its kind to receive FDA IND clearance.¹

Leadership also changed hands: Legend appointed Ingrid Zhang as Chief Executive Officer effective September 15, 2026, succeeding Alan Bash, who had served as Interim CEO since July 2026 and returned to his role as President, CARVYKTI.¹

Financially, operating income was $46.8 million for the quarter versus an operating loss of $43.3 million a year earlier, and net income was $51.7 million compared with a net loss of $39.6 million in the prior-year quarter.¹ The company reported cash and cash equivalents and time deposits totaling roughly $853 million as of September 30, 2026.¹